抗菌治療薬の世界市場

抗菌治療薬の世界市場は2030年までに1,489億米ドルに到達

2024年に1,129億米ドルと推定される抗菌治療薬の世界市場は、分析期間2024-2030年にCAGR 4.7%で成長し、2030年には1,489億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗菌薬は、CAGR 5.5%を記録し、分析期間終了時には584億米ドルに達すると予想されます。抗ウイルス薬セグメントの成長率は、分析期間中CAGR 5.1%と推定されます。

米国市場は308億米ドルと推定、中国はCAGR 8.7%で成長予測

米国の抗菌治療薬市場は2024年に308億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに313億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.9%と3.7%と予測されています。欧州では、ドイツがCAGR 2.8%で成長すると予測されています。

世界の抗菌治療薬市場- 主要動向と促進要因のまとめ

なぜ抗菌治療薬が世界ヘルス、感染管理、臨床成果の中心なのか？

抗菌治療薬は現代医学の基礎であり、細菌、ウイルス、真菌、寄生虫による感染症の治療と予防を可能にします。その役割は、急性疾患の治療にとどまらず、日常的な手術、免疫抑制療法、臓器移植、がん治療の成果を守るために不可欠です。病原微生物を標的とし中和することで、これらの薬剤は罹患率、死亡率、感染率を減少させ、世界的に公衆衛生防御システムの基幹を形成しています。

抗生物質は、市中肺炎から敗血症、多剤耐性結核まで、幅広い細菌感染症に対応し、このグループの中で最も広く使用されています。抗ウイルス薬は、HIV、肝炎、インフルエンザなどの感染症の制圧に極めて重要な役割を果たし、抗真菌薬や抗寄生虫薬は、腫瘍学や熱帯病の管理に不可欠です。病院環境では、特に集中治療室、移植センター、腫瘍病棟など、免疫不全患者のリスクが高まる場所で、抗菌治療薬が感染制御プロトコルを支えています。

抗菌剤は、臨床治療にとどまらず、農業のバイオセキュリティ、獣医学、生物防衛の準備においても不可欠です。その幅広い有用性により、抗菌薬は世界的に最も広く処方されている治療薬のひとつとなっています。しかし、抗菌薬耐性（AMR）の増加、新たな感染症の脅威、そして世界のパンデミックにより、現在の治療薬の脆弱性が露呈しつつあり、抗菌薬のイノベーションとスチュワードシップは、世界ヘルスの課題としてますます緊急性を増しています。

イノベーション戦略と科学的進歩は、抗菌薬開発の未来をどのように形成しているのか？

新しいテーマの発見と開発は、生物学的な複雑さ、規制のハードル、商業的インセンティブの低さなどの制約を長い間受けてきました。しかし、最近のゲノミクス、ハイスループットスクリーニング、構造ベースのドラッグデザイン、マイクロバイオーム研究の進歩は、創薬パイプラインを活性化しつつあります。細菌の病原性因子の阻害、クオラムセンシング阻害剤、宿主と病原体のインターフェイス破壊剤など、新たな作用機序の開発が、耐性菌の発生を回避し、治療効果を持続させるために進められています。

長時間作用型の注射薬、吸入抗菌薬、ナノ粒子ベースのデリバリーシステムは、特に骨髄炎、心内膜炎、慢性肺疾患のような到達困難な感染症において、薬物動態、ターゲティング、バイオアベイラビリティを改善しています。さらに、抗体ベースの抗菌薬やバクテリオファージ療法は、広域抗生物質の精密な代替薬として注目を集めています。これらの生物学的製剤は、宿主の微生物叢を維持しながら特定の病原体を標的にする可能性があり、耐性菌や付随的損害のリスクを軽減します。

また、プッシュ型インセンティブ（助成金、研究開発補助金）やプル型メカニズム（市場参入報奨金、契約金）といった新たな経済モデルのもと、公的機関、世界ヘルスNGO、民間開発者の協力によって開発が推進されています。CARB-X、GARDP、AMR Action Fundなどのプログラムは、初期段階の研究に資金を提供し、重要な病原体を標的とする新規抗菌薬の開発パイプラインのリスクを軽減しています。高ニーズ、低リターンのこの領域で持続可能なイノベーションを実現するための新たなパラダイムが出現するにつれ、市場は科学的、商業的実現可能性のギャップに対処する方向へと徐々に位置づけを変えつつあります。

抗菌ソリューションの需要を牽引している治療領域と地域市場は？

呼吸器感染症、尿路感染症（UTI）、皮膚・軟部組織感染症、院内感染（HAI）は、依然として抗菌薬使用の最大治療分野です。パンデミック後の状況において、インフルエンザ、COVID-19、RSVを含むウイルス性呼吸器疾患は、幅広い抗ウイルス剤への備えの必要性に対する認識を高めています。細菌性肺炎、結核、淋病、および多剤耐性病原体が入院・外来の両方で引き続き流行しているため、すべての抗菌薬クラスにおいて基本的な需要が強く維持されています。

特にアジア太平洋、サハラ以南のアフリカ、ラテンアメリカの高負荷疾患地域では、必要不可欠な医薬品へのアクセス拡大、抗菌薬スチュワードシップ・プログラムの拡大、政府主導の感染制御イニシアチブにより、使用量が増加しています。新興経済諸国では、AMR率の上昇、人口の高齢化、病院での処置件数の増加が、MRSA、CRE、VREなどの多剤耐性菌に対応する次世代治療薬への需要を促進しています。同時に、地域レベルでのウイルスの流行や慢性疾患の併存が、持続的かつ広範な抗菌薬使用の必要性を高めています。

小児および老年人口は、感染症にかかりやすく、ポリファーマシーに頻繁にさらされることから、重要な需要層です。また、抗菌薬の予防的使用や経験的使用が必要となる免疫不全の状態にある腫瘍、重症患者、移植患者も大量に使用されます。世界のヘルスケアの焦点がユニバーサル・ヘルス・カバレッジとパンデミックへの耐性にシフトする中、抗菌治療薬は世界的に必須医療と緊急医療の両方の枠組みの中心にあり続けています。

耐性圧力、規制の枠組み、スチュワードシップへの取り組みは、市場のダイナミクスをどのように変えているのか？

抗菌薬耐性は、既存薬剤クラスの陳腐化を加速させ、医療費、罹患率、死亡率を上昇させることにより、市場を再構築しています。AMRは現在、年間120万人の命を奪っていると推定され、このままでは2050年までにがんを上回る主要な死因になると予測されています。規制当局は、耐性菌の開発を遅らせ、合理的な薬剤使用を促進するため、スチュワードシップ方針の強化、監視プログラム、処方管理を義務付けています。このようなシフトは、ヘルスケアシステム全体の処方行動や調達の優先順位に直接的な影響を及ぼしています。

FDA、EMA、WHOなどの機関は、緊急に必要とされる抗菌薬を迅速に提供するために、適格感染症製品（QIDP）指定や早期審査の仕組みなど、合理化された規制経路を導入しています。同時に、抗菌薬使用のベンチマーク、処方制限、病院レベルの抗菌薬グラム追跡などの政策により、正確な使用が奨励され、経験的な過剰使用が削減されつつあります。医薬品開発企業は、新製品を上市する際に、有効性だけでなく生態学的安全性や耐性菌の可能性の低さも証明するよう、ますます強く求められています。

スチュワードシップとサーベイランスは病院運営に不可欠なものとなりつつあり、多くの場合、診療報酬や認定基準と関連しています。迅速な病原体同定、感受性検査、電子処方監査などのデジタルツールや診断技術革新は、エビデンスに基づく意思決定を支援するために、スチュワードシップ・プログラムに統合されつつあります。これらの介入は、教育的努力や国家的行動計画と相まって、抗菌薬の価値提案をコモディティ医薬品から戦略的に管理された治療資産へと再定義しつつあります。

抗菌治療薬市場の成長を促進する要因は何か？

世界の抗菌治療薬市場は、感染症の蔓延、抗菌薬耐性の上昇、COVID-19後の公衆衛生への新たな投資によって拡大しています。プライマリ・ケア、病院環境、専門医療における継続的な需要は、急性期治療と慢性期治療のサポートにおける抗菌薬の重要な役割を裏付けています。市場開拓は、新たな感染症の脅威、人口の高齢化、世界の旅行、新興国市場での医療アクセスの拡大によってさらに後押しされています。

耐性、価格圧力、研究開発リスクが商業的な持続可能性に引き続き課題している一方で、協調的な資金調達モデル、革新的なパイプライン戦略、進化する規制支援によって情勢は再構築されつつあります。標的生物学的製剤、新しい投与形態、デジタル診断薬の台頭は、効果的な次世代抗菌薬治療のあり方を再定義しつつあります。同時に、社会的認識、政策的義務、ESGに沿った製薬戦略は、持続可能な抗生物質開発と責任ある市場開拓の必要性を強めています。

今後、抗菌治療薬市場の将来は、イノベーション、アクセス、耐性抑制のバランスをいかにうまく取れるかにかかっています。病原体が進化し、治療格差が広がる中、精密に設計され、スチュワードシップが統合された新世代の抗菌薬が、世界の健康安全保障の最前線を守る存在として登場する可能性はあるのだろうか。

セグメント

薬剤クラス別（抗菌薬、抗ウイルス薬、抗真菌薬、抗寄生虫薬）、適応疾患（呼吸器感染症、尿路感染症、皮膚・軟部組織感染症、性感染症、消化器感染症、中枢神経系感染症、その他の適応疾患）、投与経路（経口剤、局所剤、注射剤、その他の投与経路）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の47社）

• AbbVie Inc.
• Allecra Therapeutics GmbH
• Aridis Pharmaceuticals, Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Basilea Pharmaceutica Ltd.
• Bayer AG
• BioVersys AG
• Bristol-Myers Squibb Company
• Cadila Pharmaceuticals Ltd.
• Cipla Ltd.
• CSL Limited
• Eli Lilly and Company
• Emergent BioSolutions Inc.
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson
• KYORIN Pharmaceutical Co., Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Antimicrobial Therapeutics Market to Reach US$148.9 Billion by 2030

The global market for Antimicrobial Therapeutics estimated at US$112.9 Billion in the year 2024, is expected to reach US$148.9 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Antibacterial Drugs, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$58.4 Billion by the end of the analysis period. Growth in the Antiviral Drugs segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$30.8 Billion While China is Forecast to Grow at 8.7% CAGR

The Antimicrobial Therapeutics market in the U.S. is estimated at US$30.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$31.3 Billion by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Antimicrobial Therapeutics Market - Key Trends & Drivers Summarized

Why Are Antimicrobial Therapeutics Central to Global Health, Infection Control, and Clinical Outcomes?

Antimicrobial therapeutics are foundational to modern medicine, enabling the treatment and prevention of infections caused by bacteria, viruses, fungi, and parasites. Their role extends far beyond treating acute illnesses-they are essential for safeguarding outcomes in routine surgeries, immunosuppressive therapies, organ transplants, and cancer care. By targeting and neutralizing pathogenic microorganisms, these drugs reduce morbidity, mortality, and transmission rates, forming the backbone of public health defense systems globally.

Antibiotics remain the most widely used class within this group, addressing bacterial infections ranging from community-acquired pneumonia to sepsis and multidrug-resistant tuberculosis. Antivirals play a pivotal role in controlling infections such as HIV, hepatitis, and influenza, while antifungals and antiparasitics are indispensable in oncology and tropical disease management. In hospital settings, antimicrobial therapeutics underpin infection control protocols, especially in intensive care units, transplant centers, and oncology wards, where immunocompromised patients are at heightened risk.

Beyond clinical care, antimicrobial agents are vital in agricultural biosecurity, veterinary medicine, and biodefense preparedness. Their broad utility has made them among the most widely prescribed therapeutic categories globally. However, rising antimicrobial resistance (AMR), emerging infectious disease threats, and global pandemics are exposing the vulnerabilities of current therapeutic arsenals, making antimicrobial innovation and stewardship increasingly urgent on the global health agenda.

How Are Innovation Strategies and Scientific Advances Shaping the Future of Antimicrobial Development?

The discovery and development of new antimicrobial therapeutics have long been constrained by biological complexity, regulatory hurdles, and low commercial incentives. However, recent advances in genomics, high-throughput screening, structure-based drug design, and microbiome research are reinvigorating drug discovery pipelines. Novel mechanisms of action-such as inhibition of bacterial virulence factors, quorum sensing blockers, and host-pathogen interface disruptors-are being explored to circumvent resistance development and prolong therapeutic efficacy.

Long-acting injectables, inhaled antimicrobials, and nanoparticle-based delivery systems are improving pharmacokinetics, targeting, and bioavailability-particularly in hard-to-reach infections like osteomyelitis, endocarditis, and chronic lung disease. Additionally, antibody-based antimicrobials and bacteriophage therapies are gaining attention as precision alternatives to broad-spectrum antibiotics. These biologics offer the potential to target specific pathogens while preserving the host microbiota, reducing the risk of resistance and collateral damage.

Innovation is also being driven by collaborations between public agencies, global health NGOs, and private developers under new economic models such as push incentives (grants, R&D subsidies) and pull mechanisms (market entry rewards, subscription payments). Programs like CARB-X, GARDP, and the AMR Action Fund are funding early-stage research and derisking development pipelines for novel antimicrobials targeting critical pathogens. As new paradigms emerge for sustainable innovation in this high-need, low-return domain, the market is gradually repositioning itself toward addressing both scientific and commercial viability gaps.

Which Therapeutic Areas and Regional Markets Are Driving Demand for Antimicrobial Solutions?

Respiratory infections, urinary tract infections (UTIs), skin and soft tissue infections, and hospital-acquired infections (HAIs) remain the largest therapeutic areas for antimicrobial use. In the post-pandemic landscape, viral respiratory diseases-including influenza, COVID-19, and RSV-have heightened awareness of the need for broad-spectrum antiviral preparedness. The continued prevalence of bacterial pneumonia, tuberculosis, gonorrhea, and multidrug-resistant pathogens in both inpatient and outpatient settings is sustaining strong baseline demand across all antimicrobial classes.

High-burden disease regions-particularly in Asia-Pacific, Sub-Saharan Africa, and Latin America-are seeing rising usage due to expanding access to essential medicines, growing antimicrobial stewardship programs, and government-led infection control initiatives. In developed economies, rising rates of AMR, aging populations, and increasing hospital procedural volumes are driving demand for next-generation therapeutics that address multidrug-resistant organisms such as MRSA, CRE, and VRE. Concurrently, community-level viral outbreaks and chronic disease comorbidities are amplifying the need for sustained, broad-based antimicrobial availability.

Pediatric and geriatric populations represent critical demand segments, given their higher susceptibility to infections and frequent exposure to polypharmacy. Oncology, critical care, and transplant patients also generate high-volume usage due to immunocompromised conditions that necessitate prophylactic and empiric antimicrobial use. With the global healthcare focus shifting toward universal health coverage and pandemic resilience, antimicrobial therapeutics remain at the center of both essential and emergency care frameworks worldwide.

How Are Resistance Pressures, Regulatory Frameworks, and Stewardship Efforts Reshaping Market Dynamics?

Antimicrobial resistance is reshaping the market by accelerating the obsolescence of existing drug classes and driving up healthcare costs, morbidity, and mortality rates. AMR now claims an estimated 1.2 million lives annually and is projected to surpass cancer as a leading cause of death by 2050 if unchecked. Regulatory bodies are mandating stronger stewardship policies, surveillance programs, and prescription controls to slow resistance development and promote rational drug use. These shifts are directly influencing prescribing behavior and procurement priorities across healthcare systems.

Agencies such as the FDA, EMA, and WHO are implementing streamlined regulatory pathways-including Qualified Infectious Disease Product (QIDP) designations and accelerated review mechanisms-to fast-track urgently needed antimicrobials. At the same time, policies such as antibiotic use benchmarking, formulary restrictions, and hospital-level antibiogram tracking are encouraging precision usage and reducing empirical overuse. Pharmaceutical developers are under growing pressure to demonstrate not only efficacy but also ecological safety and low resistance potential in new product launches.

Stewardship and surveillance are becoming integral to hospital operations, often linked to reimbursement and accreditation standards. Digital tools and diagnostic innovations-such as rapid pathogen identification, susceptibility testing, and electronic prescribing audits-are being integrated into stewardship programs to support evidence-based decision-making. These interventions, combined with educational efforts and national action plans, are redefining the value proposition of antimicrobials from commodity drugs to strategically managed therapeutic assets.

What Are the Factors Driving Growth in the Antimicrobial Therapeutics Market?

The global antimicrobial therapeutics market is expanding, driven by the growing prevalence of infectious diseases, rising antimicrobial resistance, and renewed public health investment post-COVID-19. Continued demand in primary care, hospital settings, and specialty medicine underscores the essential role of antimicrobials in both acute intervention and chronic care support. Growth is further supported by emerging infectious disease threats, aging populations, global travel, and expanded access to care in developing markets.

While resistance, pricing pressure, and R&D risk continue to challenge commercial sustainability, the landscape is being reshaped by collaborative funding models, innovative pipeline strategies, and evolving regulatory support. The rise of targeted biologics, novel delivery formats, and digital diagnostics is redefining what constitutes effective, next-generation antimicrobial care. Simultaneously, public awareness, policy mandates, and ESG-aligned pharma strategies are reinforcing the need for sustainable antibiotic development and responsible market deployment.

Looking ahead, the future of the antimicrobial therapeutics market will depend on how successfully the sector can balance innovation, access, and resistance containment. As pathogens evolve and treatment gaps widen, could a new generation of precision-designed, stewardship-integrated antimicrobials emerge as the frontline defenders of global health security?

SCOPE OF STUDY:

The report analyzes the Antimicrobial Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antibacterials, Antivirals, Antifungals, Antiparasitics); Disease Indication (Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections, Gastrointestinal Infections, Central Nervous System Infections, Other Disease Indications); Administration Route (Oral, Topical, Injectable, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• AbbVie Inc.
• Allecra Therapeutics GmbH
• Aridis Pharmaceuticals, Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Basilea Pharmaceutica Ltd.
• Bayer AG
• BioVersys AG
• Bristol-Myers Squibb Company
• Cadila Pharmaceuticals Ltd.
• Cipla Ltd.
• CSL Limited
• Eli Lilly and Company
• Emergent BioSolutions Inc.
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson
• KYORIN Pharmaceutical Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Antimicrobial Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Concern Over Drug-Resistant Infections Throws the Spotlight on Antimicrobial Therapeutic Innovation
  • Growth in Hospital-Acquired Infections Spurs Demand for Broad-Spectrum and Targeted Antibiotics
  • Increased Investment in Rapid Diagnostic Tools Supports Timely and Precise Therapy Deployment
  • OEM Interest in Narrow-Spectrum and Microbiome-Friendly Drugs Fuels Next-Gen Therapeutic Development
  • Use of Phage Therapy and Antimicrobial Peptides Gains Momentum in Refractory Infection Cases
  • Expansion of Zoonotic and One Health Strategies Broadens Scope for Veterinary and Environmental Use
  • Growth in Topical and Device-Integrated Antimicrobials Supports Localized Infection Management
  • Increased Demand for Oral Formulations and Home-Based Infection Management Expands Convenience-Based Therapy
  • Global Regulatory Incentives and Fast Track Designations Enhance Commercial Viability for New Entrants
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Antimicrobial Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Antimicrobial Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Antimicrobial Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antibacterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antibacterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Antibacterials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Antivirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Antifungals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Antifungals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Antifungals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Antiparasitics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Antiparasitics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Antiparasitics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Central Nervous System Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Central Nervous System Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Central Nervous System Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Respiratory Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Respiratory Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Respiratory Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Urinary Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Urinary Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Urinary Tract Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Skin & Soft Tissue infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Skin & Soft Tissue infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Skin & Soft Tissue infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Sexually Transmitted Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Sexually Transmitted Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Sexually Transmitted Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Gastrointestinal Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Gastrointestinal Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Gastrointestinal Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 59: USA Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: USA 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Canada 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Japan 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 95: China Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 104: China Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: China 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Antimicrobial Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Antimicrobial Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Europe 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 122: France Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 131: France Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: France Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: France 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Germany 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 143: Germany Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Germany Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Germany 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Italy 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 155: Italy Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Italy Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Italy 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 158: UK Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 164: UK Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: UK 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 167: UK Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: UK Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: UK 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Spain 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 179: Spain Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Spain Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Spain 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Russia 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 191: Russia Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Russia Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Russia 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Europe Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Europe 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Antimicrobial Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Antimicrobial Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Asia-Pacific Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Asia-Pacific 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Australia 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 230: Australia Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Australia Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Australia 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 233: India Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 239: India Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: India 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 242: India Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: India Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: India 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: South Korea 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 254: South Korea Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: South Korea Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: South Korea 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Rest of Asia-Pacific Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Rest of Asia-Pacific 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Antimicrobial Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Antimicrobial Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Latin America 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 281: Latin America Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Latin America Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Latin America 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Argentina 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 293: Argentina Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Argentina Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Argentina 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Brazil 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 305: Brazil Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Brazil Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Brazil 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Mexico 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 317: Mexico Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Mexico Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Mexico 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Latin America Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Rest of Latin America 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Antimicrobial Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Antimicrobial Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Middle East 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 344: Middle East Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Middle East Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Middle East 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Iran 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 356: Iran Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Iran Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Iran 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Israel 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 368: Israel Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Israel Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Israel 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Saudi Arabia Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Saudi Arabia 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: UAE 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 392: UAE Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: UAE Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: UAE 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Rest of Middle East Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Rest of Middle East 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Antimicrobial Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Antimicrobial Therapeutics by Drug Class - Antibacterials, Antivirals, Antifungals and Antiparasitics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Antimicrobial Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibacterials, Antivirals, Antifungals and Antiparasitics for the Years 2015, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Antimicrobial Therapeutics by Disease Indication - Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for Antimicrobial Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Central Nervous System Infections, Other Disease Indications, Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue infections, Sexually Transmitted Infections and Gastrointestinal Infections for the Years 2015, 2025 & 2030
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Antimicrobial Therapeutics by Administration Route - Oral, Topical, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 415: Africa 15-Year Perspective for Antimicrobial Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 416: Africa Recent Past, Current & Future Analysis for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Africa Historic Review for Antimicrobial Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 418: Africa 15-Year Perspective for Antimicrobial Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION